Mylan introduces generic of Upsher-Smith's Klor-Con
- The FDA has approved Mylan's ANDA for potassium chloride extended-release (ER) tablets in two separate doses.
- This is the generic version of Upsher-Smith’s Klor-Con. For the first half of the year, this product had $135.05 million in sales, according to healthcare data company IMS Health.
- Klor-Con -- and its generic equivalent -- treats patients with hypokalemia with or without metabolic alkalosis. It also treats patients with hypokalemic familial periodic paralysis.
Mylan boasts a portfolio of more than 1,300 generic medications on top of several branded products. The company also provides an assortment of antiretroviral therapies that are used on a widespread basis. In fact, 40% of HIV/AIDS patients in developing countries use Mylan medications.
Furthermore, Mylan is a large manufacturer of active pharmaceutical ingredients (APIs). With business in 140 countries and 29 pending ANDAs, Mylan continues to be a major player in the generic drug industry.
- Pharmaceutical Business Review Mylan introduces first generic Klor-Con extended-release tablets for hypokalemia treatment